A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE AND MULTIPLE ASCENDING ORAL DOSES OF PF-06414300 ADMINISTERED AS IMMEDIATE AND MODIFIED RELEASE FORMULATIONS IN HEALTHY ADULT PARTICIPANTS
Latest Information Update: 31 Oct 2024
At a glance
- Drugs PF 06414300 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Pfizer
- 31 Oct 2024 New trial record